Infant Bacterial Therapeutics AB (publ)
Research Infant Bacterial Therapeutics AB (publ) (IBT-B) on Bullrun: market cap SEK 879.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIBT-B
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 879.68M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 22.94M
- Free cash flow-SEK 12.42M
Valuation Snapshot
latest market cap is SEK 879.68M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 65.17M | -SEK 72.34M | n/a | -4.84 | SEK 144.01M | n/a | SEK 105.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 879.68M | n/a | n/a | n/a |
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Infant Bacterial Therapeutics AB (publ)'s market cap?
Infant Bacterial Therapeutics AB (publ)'s market capitalization is SEK 879.68M.
What does Infant Bacterial Therapeutics AB (publ) do?
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants.